# Linzagolix in Adenomyosis and Recurrent Implantation Failure

> **NCT07698561** · — · NOT_YET_RECRUITING · sponsor: **Vida Fertility Institute** · enrollment: 35 (estimated)

## Conditions studied

- Adenomyosis of Uterus
- Implantation Failure
- Infertility Female
- Embryo Transfer

## Interventions

- **DRUG:** Linzagolix 200 mg (Yselty)

## Key facts

- **NCT ID:** NCT07698561
- **Lead sponsor:** Vida Fertility Institute
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698561, "Linzagolix in Adenomyosis and Recurrent Implantation Failure". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*